- Report
- April 2024
- 30 Pages
Global
From €2958EUR$3,250USD£2,512GBP
- Report
- October 2021
- 131 Pages
Global
From €13648EUR$14,995USD£11,592GBP
- Drug Pipelines
- September 2019
- 141 Pages
Global
€9102EUR$10,000USD£7,731GBP
Keytruda is a type of skin cancer drug used to treat melanoma, a type of skin cancer. It is a type of immunotherapy, which works by helping the body’s immune system recognize and attack cancer cells. Keytruda is a monoclonal antibody, which means it is designed to target a specific protein on the surface of cancer cells. It is approved for use in adults and children with advanced melanoma, and is also being studied for use in other types of cancer.
Keytruda is one of several skin cancer drugs on the market. Other drugs used to treat melanoma include Yervoy, Opdivo, and Tecentriq. These drugs are all immunotherapies, and work in different ways to help the body fight cancer.
Companies in the Keytruda market include Merck, which manufactures the drug, as well as Bristol-Myers Squibb, Roche, and AstraZeneca. These companies are all involved in the research, development, and marketing of Keytruda and other skin cancer drugs. Show Less Read more